I期临床-话题@MedSci

#I期临床#

570篇内容 | 7014人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652812, encodeId=dbab16528125d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：用于实体瘤治疗的全新human double minute 2（HDM2）拮抗剂SAR405838的I期临床研究, objectType=article, longId=124752, objectId=fc20124e5249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc20124e5249, replyNumber=0, likeNumber=62, createdTime=2018-11-26, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc20124e5249, moduleTitle=EUR J Cancer：用于实体瘤治疗的全新human double minute 2（HDM2）拮抗剂SAR405838的I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc20124e5249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652817, encodeId=d4be165281e05, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, objectType=article, longId=126123, objectId=8fa3126123fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa3126123fa, replyNumber=0, likeNumber=70, createdTime=2018-02-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa3126123fa, moduleTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa3126123fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652799, encodeId=57191652e9969, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：埃博拉疫苗III期临床研究, objectType=article, longId=115953, objectId=514d11595351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514d11595351, replyNumber=0, likeNumber=85, createdTime=2017-10-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514d11595351, moduleTitle=NEJM：埃博拉疫苗III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=514d11595351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652794, encodeId=eaa61652e94b8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, objectType=article, longId=107035, objectId=461b10e035bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461b10e035bf, replyNumber=0, likeNumber=60, createdTime=2017-12-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461b10e035bf, moduleTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461b10e035bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652801, encodeId=a5bb165280163, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CLIN CANCER RES：Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果, objectType=article, longId=118031, objectId=498d118031bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=498d118031bc, replyNumber=0, likeNumber=73, createdTime=2018-06-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=498d118031bc, moduleTitle=CLIN CANCER RES：Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=498d118031bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652820, encodeId=757f165282040, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, objectType=article, longId=130729, objectId=edaa130e2993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edaa130e2993, replyNumber=0, likeNumber=59, createdTime=2018-09-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edaa130e2993, moduleTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edaa130e2993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652793, encodeId=1a5e1652e937a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, objectType=article, longId=103410, objectId=211c103410c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=211c103410c6, replyNumber=0, likeNumber=71, createdTime=2017-07-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=211c103410c6, moduleTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=211c103410c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652800, encodeId=45a1165280079, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, objectType=article, longId=117236, objectId=41dc11e236e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41dc11e236e9, replyNumber=0, likeNumber=48, createdTime=2018-03-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41dc11e236e9, moduleTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41dc11e236e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652807, encodeId=945b165280e8e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, objectType=article, longId=124106, objectId=bed9124106d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed9124106d6, replyNumber=0, likeNumber=60, createdTime=2018-06-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed9124106d6, moduleTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed9124106d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652797, encodeId=09271652e9705, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CLIN CANCER RES：TAK-117治疗晚期恶性肿瘤Ⅰ期临床试验结果, objectType=article, longId=112044, objectId=bb781120446e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb781120446e, replyNumber=0, likeNumber=66, createdTime=2018-03-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb781120446e, moduleTitle=CLIN CANCER RES：TAK-117治疗晚期恶性肿瘤Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb781120446e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652814, encodeId=0a60165281413, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, objectType=article, longId=125185, objectId=de17125185b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de17125185b2, replyNumber=0, likeNumber=78, createdTime=2018-08-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de17125185b2, moduleTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de17125185b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652785, encodeId=3aa01652e8591, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, objectType=article, longId=93569, objectId=376693569b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376693569b4, replyNumber=0, likeNumber=77, createdTime=2018-01-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376693569b4, moduleTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376693569b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652782, encodeId=29501652e824c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CHEST：西罗莫司和自噬抑制对LAM治疗效果的I期临床试验, objectType=article, longId=89044, objectId=75b08904459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75b08904459, replyNumber=0, likeNumber=53, createdTime=2017-05-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75b08904459, moduleTitle=CHEST：西罗莫司和自噬抑制对LAM治疗效果的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75b08904459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652806, encodeId=01d316528064f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, objectType=article, longId=123310, objectId=7e0a123310a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e0a123310a5, replyNumber=0, likeNumber=28, createdTime=2018-04-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e0a123310a5, moduleTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e0a123310a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652809, encodeId=3ab016528099f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, objectType=article, longId=124481, objectId=c81c12448125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c81c12448125, replyNumber=0, likeNumber=56, createdTime=2018-09-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c81c12448125, moduleTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c81c12448125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652792, encodeId=5d731652e92e6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Blood: selinexor治疗急性骨髓性白血病的I期临床试验, objectType=article, longId=102914, objectId=1daa10291491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1daa10291491, replyNumber=0, likeNumber=74, createdTime=2017-12-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1daa10291491, moduleTitle=Blood: selinexor治疗急性骨髓性白血病的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1daa10291491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652798, encodeId=59521652e98ba, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, objectType=article, longId=113798, objectId=4275113e9856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4275113e9856, replyNumber=0, likeNumber=82, createdTime=2018-06-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4275113e9856, moduleTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4275113e9856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652803, encodeId=1ba616528031a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, objectType=article, longId=120485, objectId=e3de120485e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3de120485e7, replyNumber=0, likeNumber=67, createdTime=2018-06-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3de120485e7, moduleTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3de120485e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652789, encodeId=33ae1652e8946, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展, objectType=article, longId=101269, objectId=286810126909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286810126909, replyNumber=0, likeNumber=66, createdTime=2017-10-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286810126909, moduleTitle=ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286810126909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652802, encodeId=aca816528027d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果, objectType=article, longId=118500, objectId=27dc1185009a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27dc1185009a, replyNumber=0, likeNumber=73, createdTime=2018-08-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27dc1185009a, moduleTitle=NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27dc1185009a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

仁心济世 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：用于实体瘤治疗的全新human double minute 2（HDM2）拮抗剂SAR405838的I期临床研究

2018-11-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败

2018-02-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：埃博拉疫苗III期临床研究

2017-10-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险

2017-12-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CLIN CANCER RES：Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果

2018-06-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究

2018-09-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）

2017-07-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究

2018-03-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验

2018-06-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CLIN CANCER RES：TAK-117治疗晚期恶性肿瘤Ⅰ期临床试验结果

2018-03-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验

2018-08-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究

2018-01-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CHEST：西罗莫司和自噬抑制对LAM治疗效果的I期临床试验

2017-05-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著

2018-04-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

2018-09-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Blood: selinexor治疗急性骨髓性白血病的I期临床试验

2017-12-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

肾性贫血首创药罗沙司他III期临床研究结果发布

2018-06-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%

2018-06-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展

2017-10-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果

2018-08-22

科室
- - 订阅+
  - 更多科室
工具
服务